trialrating

190 results found.

Top Stocks matching your search for "trial rating"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 15, 2023

$SAVA β€œTreatment also eased depression and dementi... See more

Feb, 6, 2023

Simufilam reduced dementia-related behavior at 9 m... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
HTGM

HTG Molecular Diagnostics Inc

-37.26%

$4.67 - $2.93

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 20, 2023

Monday morning pre-market screamer 😱 candidates: ... See more

Dec, 20, 2022

SIMILAR SETUP TO $AMAM, $HTGM, $APVO, $APCX Vo... See more

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
PHVS

Pharvaris NV

-30.10%

$9.60 - $6.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Dec, 10, 2022

$PHAR Good news for competitor Pharvaris $PHVS, ... See more

Dec, 9, 2022

$PHVS Look at this company, this could be Athenex ... See more

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 15, 2023

$SAVA β€œTreatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

Feb, 6, 2023

Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.

Feb, 1, 2023

The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.

Jan, 17, 2023

$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.

Jan, 6, 2023

$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.

Jan, 4, 2023

$SAVA , VERA announced positive phase 2b results meeting primary end point.

Dec, 27, 2022

My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients

HTGM

HTG Molecular Diagnostics Inc

-37.26%

$4.67 - $2.93

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Jan, 20, 2023

Monday morning pre-market screamer 😱 candidates: πŸš¨πŸš¨πŸš¨πŸ’ŽπŸ’ŽπŸ’ŽπŸ”₯πŸ”₯πŸ”₯ $TCBP Phase 2 update still pending-huge potential on this nano float $BOXD over $1 easy $ALLR PT $.50 $HTGM she’s ready for another big run This week was very good to me.

Dec, 20, 2022

SIMILAR SETUP TO $AMAM, $HTGM, $APVO, $APCX Volume increasing since last week βœ… Low float recent IPO βœ… Strong future trial pipeline βœ… Time for the next leg up towards IPO price!

Dec, 11, 2022

SHOULD be some awesome opportunities this week, study study study!

Dec, 9, 2022

$ATNM positive news in their acute myeloid leukemia trials πŸ‘‡πŸΌ 53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches It's time to get in before we blast off to $12+ next!

PHVS

Pharvaris NV

-30.10%

$9.60 - $6.71

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Dec, 10, 2022

$PHAR Good news for competitor Pharvaris $PHVS, published interim results of the oral on demand threatment Phase II study which are good!

Dec, 9, 2022

$PHVS Look at this company, this could be Athenex in 2 weeks.. this went up 400% in one day on positive phase 2 data.

Dec, 9, 2022

$LXRX $PHVS goes up 340% on phase 1/2 top line read out

Dec, 9, 2022

$PHVS Trials blocked in US with drug on clinical hold and this goes up 340%.

Dec, 9, 2022

this stock was forever doing nothing languishing at a range of $2 to $3 then all of a sudden, they announce great clinical results and BAMM the stock goes up 339% in ONE DAY!! .

Dec, 8, 2022

That’s how these successful trials run %wise.

Dec, 8, 2022

460k float, amazing news on trial commencement

Dec, 8, 2022

$PHVS what a run on phase 2 results, good short here